

Angiopoietin 2 (Ang - 2) Inhibitor - Pipeline Review - 2019

<https://marketpublishers.com/r/AA8827664A45EN.html>

Date: November 2019

Pages: 58

Price: US\$ 1,250.00 (Single User License)

ID: AA8827664A45EN

Abstracts

Firstview Market Insight "Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019" provides an overview of the pipeline landscape for Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019. It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc. These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.

Angiopoietins are Tie2 receptor ligands that play key roles in vascular development, angiogenesis, and remodeling. Angiopoietin-1 (Ang1) tends to stabilize blood vessels and promote vascular maturation. Ang2 is expressed in growing blood vessels and promotes angiogenesis and tumor growth by destabilizing blood vessels. Vascular destabilization may involve Ang2 acting as an inhibitor or partial agonist of Tie2, which opposes the stabilizing action of Ang1 on endothelial cells. Inhibition of Ang2 may promote vessel stability and reduce angiogenesis thus inhibiting tumor progression. Multiple approaches have been used to inhibit Ang2 to explore effects on angiogenesis and tumor growth. Among these are genetic deletion of host-derived Ang2, neutralization of angiopoietins by soluble Tie2 receptors that function as decoys, selective Ang2-binding aptamers, and antibodies and peptibodies (peptide-Fc fusion proteins) that selectively neutralize the action of Ang2.

Angiopoietin 2 (Ang-2) Inhibitors have been developed for the treatment of pancreatic, lung, colon breast, prostate carcinoma and NSCLC.

In the last four decades the recognition of a tumor's fundamental need of an expanding blood vessel network for successful development and growth has led to the identification of novel cancer therapeutic targets. As a consequence anti-angiogenic therapy has now become a common therapeutic modality in cancer treatment. However, patients often do not respond to the currently available anti-angiogenic agents or become resistant to them upon prolonged exposure. Thus, the full potential of anti-angiogenic therapy is yet to be realized and alternate modes of angiogenesis inhibition are needed. Ang-2 is commonly upregulated in tumors and in some cancer settings correlates with advanced disease and poor prognosis. As a result Ang-2 has become a desirable therapeutic target and several Ang-2 inhibiting agents are currently in preclinical or clinical development.

Report Overview:

This part of report provides detailed description of mechanism of action which enables the client to understand the landscape of the Angiopoietin 2 (Ang-2) Inhibitor. This report covers the detailed analysis of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Overview:

This report provides extensive scenario and growth prospects of the market. This section includes the graphical representations of the future treatment landscape based on various phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. It also includes details of products which have been dormant or discontinued during the trial stages of development.

Drug Profile Overview:

The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.

Clinical Trial Overview:

This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.

Product Development Activity:

This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.

Company Overview:

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial

Scope

The report provides a competitive landscape of Angiotensin 2 (Ang-2) Inhibitor - Pipeline Review-2019

The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status

The report provides the list of companies which are the most active in the pipeline

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery

The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities

The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)

The report summarizes all the dormant and discontinued pipeline projects

The report also provides latest news for the past one year

Reasons To Buy

To identifying prominent players in the Angiotensin 2 (Ang-2) Inhibitor - Pipeline Review-2019treatment landscape

To determine the drivers; barriers and unmet need in the Angiotensin 2 (Ang-2) Inhibitor - Pipeline Review-2019treatment space

Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies

Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration

Contents

1. ANGIOPOIETIN 2 (ANG-2) INHIBITOR OVERVIEW

2. FEATURED NEWS AND PRESS RELEASES, 2018-2019

3. LIST OF COMPANIES DEVELOPING ANGIOPOIETIN 2 (ANG-2) 2019

4. LATE STAGE PRODUCTS (FILED & PHASE III)

4.1. Faricimab: Phase III

4.1.1. Product Description

4.1.2. Research and Development

4.1.3. Product Development Activities

5. MID STAGE PRODUCTS (PHASE II)

5.1. Aflibercept/nesvacumab:

5.1.1. Product Description

5.1.2. Research and Development

5.1.3. Product Development Activities

6. EARLY STAGE PRODUCTS (PHASE I AND IND)

6.1. LY 3207447: Phase I

6.1.1. Product Description

6.1.2. Research and Development

6.1.3. Product Development Activities

7. PRE-CLINICAL AND DISCOVERY PRODUCTS

7.1. LY 3207447

7.1.1. Product Description

7.1.2. Research and Development

7.1.3. Product Development Activities

7.2. ABP 201

7.2.1. Product Description

7.2.2. Research and Development

7.2.3. Product Development Activities

7.3. ABP 200

7.3.1. Product Description

7.3.2. Research and Development

7.3.3. Product Development Activities

8. DRIVERS OF ANGIOPOIETIN 2 (ANG-2) INHIBITOR

9. CONSTRAINTS OF ANGIOPOIETIN 2 (ANG-2) INHIBITOR

10. THERAPEUTIC ASSESSMENT

10.1. Assessment by Route of Administration

10.2. Assessment by Phase & Route of Administration

10.3. Assessment by Molecule Type

10.4. Assessment by Phase & Molecule type

10.5. Assessment by Target

10.6. Assessment by Mechanism of Action

11. COLLABORATIONS AND ACQUISITIONS DETAILS

12. DORMANT PRODUCTS

13. DISCONTINUED PRODUCTS

14. MARKET TRENDS

15. MARKET OPPORTUNITY ASSESSMENT

16. UNMET NEEDS

17. SWOT ANALYSIS

18. APPENDIX

19. REPORT METHODOLOGY

20. CONSULTING SERVICES

21. DISCLAIMER

List Of Tables

LIST OF TABLES

Table 1: Marketed and Pipeline Angiotensin 2 (Ang-2) Inhibitor - Pipeline Review-2019 drugs, 2019

Table 2: Sales of Marketed drugs, 2019

Table 3: Patent expiration details – marketed drugs, 2019

Table 4: Number of Products Under Development for Angiotensin 2 (Ang-2) Inhibitor - Pipeline Review-2019, 2019

Table 5: Products under Development by Companies, 2019

Table 6: Late Stage Products, 2019

Table 7: Mid Stage Products, 2019

Table 8: Early Stage Products, 2019

Table 9: Pre-Clinical and Discovery Products, 2019

Table 10: Assessment by Route of Administration, 2019

Table 11: Assessment by Stage and Route of Administration, 2019

Table 12: Assessment by Molecule Type, 2019

Table 13: Assessment by Stage and Molecule Type, 2019

Table 14: Assessment by Target, 2019

Table 15: Assessment by Mechanism of Action, 2019

Table 16: Dormant Products, 2019

Table 17: Discontinued Products, 2019

List Of Figures

LIST OF FIGURES

Figure 1: Marketed and Pipeline Angiotensin 2 (Ang-2) Inhibitor - Pipeline Review-2019 drugs, 2019

Figure 2: Sales of Marketed drugs, 2019

Figure 3: Patent expiration details – marketed drugs, 2019

Figure 4: Number of Products Under Development for Angiotensin 2 (Ang-2) Inhibitor - Pipeline Review-2019, 2019

Figure 5: Products under Development by Companies, 2019

Figure 6: Late Stage Products, 2019

Figure 7: Mid Stage Products, 2019

Figure 8: Early Stage Products, 2019

Figure 9: Pre-Clinical and Discovery Products, 2019

Figure 10: Assessment by Route of Administration, 2019

Figure 11: Assessment by Stage and Route of Administration, 2019

Figure 12: Assessment by Molecule Type, 2019

Figure 13: Assessment by Stage and Molecule Type, 2019

Figure 14: Assessment by Target, 2019

Figure 15: Assessment by Mechanism of Action, 2019

Figure 16: Dormant Products, 2019

Figure 17: Discontinued Products, 2019

I would like to order

Product name: Angiopoietin 2 (Ang - 2) Inhibitor - Pipeline Review - 2019

Product link: <https://marketpublishers.com/r/AA8827664A45EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA8827664A45EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970